C.M. Bidwell & Associates’s Medifast MED Stock Holding History

C.M. Bidwell & Associates’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.27K	Buy	+497	New	+$5.73K	﹤0.01%	335
2021 Q4	–	Sell	-182	Closed	-$35K	–	601
2021 Q3	$35K	Sell	182 -31	-15%	-$7.62K	0.02%	334
2021 Q2	$60K	Buy	213 +22	+12%	+$5.96K	0.04%	290
2021 Q1	$40K	Buy	191 +40	+26%	+$9.57K	0.03%	314
2020 Q4	$30K	Sell	151 -650	-81%	-$115K	0.02%	320
2020 Q3	$132K	Buy	+801	New	+$132K	0.12%	165
2019 Q1	–	Sell	-215	Closed	-$27K	–	446
2018 Q4	$27K	Sell	215 -295	-58%	-$50.5K	0.03%	285
2018 Q3	$113K	Buy	510 +195	+62%	+$39.5K	0.11%	173
2018 Q2	$50K	Sell	315 -225	-42%	-$28.8K	0.05%	245
2018 Q1	$50K	Sell	540 -905	-63%	-$67.6K	0.05%	238
2017 Q4	$101K	Buy	+1,445	New	+$95.9K	0.09%	208
2016 Q3	–	Sell	-2,365	Closed	-$79K	–	296
2016 Q2	$79K	Buy	+2,365	New	+$76.3K	0.02%	197

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

C.M. Bidwell & Associates's MED Position: Q2 2026 in Review

C.M. Bidwell & Associates opened a new position in Medifast (MED) in Q2 2026: 497 shares worth $5.27K. The stake represents ﹤0.01% of the portfolio and ranks #335 among its holdings. This is a return to the name: C.M. Bidwell & Associates previously reported a position in MED as recently as Q3 2021.

C.M. Bidwell & Associates first reported a position in MED in Q2 2016 and has held it in 12 quarters since. The position peaked at $132K in Q3 2020. 113 funds tracked by Wall St. Rank hold MED as of Q2 2026.

C.M. Bidwell & Associates held 497 shares of Medifast worth $5.27K as of Q2 2026.
Medifast was a new C.M. Bidwell & Associates position in Q2 2026.
Medifast made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #335 holding.
C.M. Bidwell & Associates first reported a position in Medifast in Q2 2016 and has held it in 12 quarters since.
C.M. Bidwell & Associates's Medifast position peaked at $132K in Q3 2020.
113 funds tracked by Wall St. Rank held Medifast as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.